Panacea Biotec
Panacea Biotec Share Price Chart
Panacea Biotec last traded at ₹347.85 (2026-10-13). Over the past month the stock moved -10.0%, three months the stock moved -18.0%, year the stock moved -18.6%. Its closing range over 52 weeks is ₹319.80 – ₹446.50, with the latest close 22.1% below the high.
Closing prices up to 2026-10-13.
About Panacea Biotec
Incorporated in 1984, Panacea Biotec Ltd is a research-based biotechnology company[1]
Business Overview:[1] a) PBL is in the business of research, development, manufacture and marketing of branded vaccines, pharmaceutical formulations, nutraceuticals and food & nutrition products b) It is one of the largest Vaccine Manufacturing Company in India and is acknowledged by the United Nations (UN) Health Agencies in partnering the Global Polio Eradication Initiative (GPEI) with supplies of billions of doses of WHO Pre-qualified Polio vaccines in 50+ countries worldwide as a sequel to the completion of full range of Oral polio vaccines (tOPV, mOPV1, mOPV3 & bOPV (Type1&Type3) c) It is the first company to have developed fully liquid Pentavalent vaccine (DTwP-Hep B+Hib) EasyFive and world’s first fully-liquid wP-IPV based Hexavalent vaccine (DTwP +HepB +Hib +IPV) EasySix
Fundamentals
Quarterly Results
In the latest quarter (Jun 2026), Panacea Biotec reported sales of ₹199.57 crore (+19.7%) and net profit of ₹2.20 crore (-44.4%), compared with the same quarter last year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Jun 2026 | 199.57 | 5.67 | 2.84 | 2.20 | 0.38 |
| Mar 2026 | 166.75 | 2.57 | 1.54 | -1.00 | 0.08 |
| Dec 2025 | 165.19 | 11.74 | 7.11 | 3.89 | 0.65 |
| Sep 2025 | 141.13 | -17.79 | -12.61 | -14.01 | -2.27 |
| Jun 2025 | 166.70 | -1.18 | -0.71 | 3.96 | 0.66 |
| Mar 2025 | 132.53 | -26.88 | -20.28 | -1.99 | -0.31 |
| Dec 2024 | 163.49 | 7.96 | 4.87 | 4.44 | 0.74 |
| Sep 2024 | 147.35 | 7.00 | 4.75 | 4.71 | 0.78 |
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | +3.0% | +8.6% | -2.9% | +44.1% | -4.2% | +1.0% | +25.8% | +19.7% |
| Operating profit growth | – | – | – | – | -354.1% | +47.5% | – | – |
| Net profit growth | – | – | – | – | -397.5% | -12.4% | – | -44.4% |
| EPS growth | – | – | – | – | -391.0% | -12.2% | – | -42.4% |
| OPM % | 4.8% | 4.9% | -20.3% | -0.7% | -12.6% | 7.1% | 1.5% | 2.8% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Annual Financials
In the latest year (Mar 2026), Panacea Biotec reported sales of ₹640.00 crore (+14.5%) and net profit of ₹-7.00 crore, compared with the previous year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 640.00 | -5.00 | -1.00 | -7.00 | -0.88 |
| Mar 2025 | 559.00 | -26.00 | -5.00 | -9.00 | -1.37 |
| Mar 2024 | 559.00 | -20.00 | -4.00 | -2.00 | -0.19 |
| Mar 2023 | 460.00 | -98.00 | -21.00 | -34.00 | -5.42 |
| Mar 2022 | 661.00 | -13.00 | -2.00 | 1,078 | 175.91 |
| Mar 2021 | 625.00 | 77.00 | 12.00 | -148.00 | -24.09 |
| Mar 2020 | 544.00 | 54.00 | 10.00 | -194.00 | -31.69 |
| Mar 2019 | 457.00 | -134.00 | -29.00 | 38.00 | 6.15 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | -22.9% | +19.0% | +14.9% | +5.8% | -30.4% | +21.5% | +0.0% | +14.5% |
| Operating profit growth | -259.5% | – | +42.6% | -116.9% | – | – | – | – |
| Net profit growth | – | -610.5% | – | – | -103.2% | – | – | – |
| EPS growth | – | -615.3% | – | – | -103.1% | – | – | – |
| OPM % | -29.0% | 10.0% | 12.0% | -2.0% | -21.0% | -4.0% | -5.0% | -1.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Shareholding
AI Analysis
No AI analysis generated yet for Panacea Biotec.
Get Free AI Stock Analysis FREE →Latest News
-
Panacea Biotec consolidated net profit declines 43.21% in the June 2026 quarter - Business Standard
-
Panacea Biotec zooms 60% in 6 days; stock hits new high on huge volumes - Business Standard
-
Panacea Biotec Soars 15% as Dengue Vaccine Candidate DengiAll Gets Global Push
-
Panacea Biotec shares soar 12% to 52-week high on launch of DENSTAR project; key details to know
-
Panacea Biotec Ltd Surges 8.26% to Day's High of Rs 432 — Outperforms Sector by 9.77 Percentage Points
-
Stock Alert: Panacea Biotec, Advance Agrolife, Zaggle Prepaid Ocean Services, Emerald Leisures, L&T - Business Standard
-
Stock Alert: Panacea Biotec, Advance Agrolife, Zaggle Prepaid Ocean Services, Emerald Leisures, L&T - Business Standard
-
Panacea Biotec, Advance Agrolife, Zaggle Prepaid Ocean Services, Emerald Leisures, L&T - Business Standard
-
Panacea Biotec, Advance Agrolife, Zaggle Prepaid Ocean Services, Emerald Leisures, L&T - Business Standard
-
Panacea Biotec bags Rs 20.79 crore LoA from Central Medical Services Society - Business Standard
Frequently Asked Questions
What is the share price of Panacea Biotec today?
Panacea Biotec shares were last quoted at ₹347.85 (+0.8% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
What is the P/E ratio of Panacea Biotec?
Panacea Biotec has a price-to-earnings (P/E) ratio of -104.61 and a price-to-book (P/B) ratio of 2.73. The industry P/E is 53.33.
What is the 52-week high and low of Panacea Biotec?
The 52-week high of Panacea Biotec is ₹647.50 and the 52-week low is ₹293.10.
What is the market cap of Panacea Biotec?
The market capitalisation of Panacea Biotec is about ₹2,280.98 crore.
How did Panacea Biotec perform in its latest quarterly results?
In the latest quarter (Jun 2026), Panacea Biotec reported sales of ₹199.57 crore (+19.7%) and net profit of ₹2.20 crore (-44.4%), compared with the same quarter last year.
Is Panacea Biotec a good stock to buy?
This page is for information and is not investment advice. As per the data shown here, Panacea Biotec has a 3-year ROE of -3.00%, 3-year profit growth of 21.00%. Review the fundamentals, quarterly results and AI analysis on StockSpin, and consult a SEBI-registered adviser before investing.
What is the promoter holding in Panacea Biotec?
Promoters hold about 72.48% of Panacea Biotec.
Which sector does Panacea Biotec belong to?
Panacea Biotec belongs to the Pharmaceuticals & Drugs sector.